Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations

  • Bernhard Kratzer
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Doris Trapin
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Paul Ettel
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Ulrike Körmöczi
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Arno Rottal
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Friedrich Tuppy
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Melanie Feichter
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Pia Gattinger
    Institute of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Kristina Borochova
    Institute of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Yulia Dorofeeva
    Institute of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Inna Tulaeva
    Institute of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Milena Weber
    Institute of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Katharina Grabmeier‐Pfistershammer
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Peter A. Tauber
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Marika Gerdov
    Department of Laboratory Medicine Medical University of Vienna Vienna Austria
  • Bernhard Mühl
    Labors.at Vienna Austria
  • Thomas Perkmann
    Department of Laboratory Medicine Medical University of Vienna Vienna Austria
  • Ingrid Fae
    Department for Blood Group Serology and Transfusion Medicine Medical University of Vienna Vienna Austria
  • Sabine Wenda
    Department for Blood Group Serology and Transfusion Medicine Medical University of Vienna Vienna Austria
  • Harald Führer
    Statistical Consultants Vienna Austria
  • Rainer Henning
    Viravaxx Vienna Austria
  • Rudolf Valenta
    Institute of Pathophysiology and Allergy Research Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
  • Winfried F. Pickl
    Institute of Immunology Center for Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>SARS‐CoV‐2 has triggered a pandemic that is now claiming many lives. Several studies have investigated cellular immune responses in COVID‐19‐infected patients during disease but little is known regarding a possible protracted impact of COVID‐19 on the adaptive and innate immune system in COVID‐19 convalescent patients.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We used multiparametric flow cytometry to analyze whole peripheral blood samples and determined SARS‐CoV‐2‐specific antibody levels against the S‐protein, its RBD‐subunit, and viral nucleocapsid in a cohort of COVID‐19 convalescent patients who had mild disease ~10 weeks after infection (n = 109) and healthy control subjects (n = 98). Furthermore, we correlated immunological changes with clinical and demographic parameters.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Even ten weeks after disease COVID‐19 convalescent patients had fewer neutrophils, while their cytotoxic CD8<jats:sup>+</jats:sup> T cells were activated, reflected as higher HLA‐DR and CD38 expression. Multiparametric regression analyses showed that in COVID‐19‐infected patients both CD3<jats:sup>+</jats:sup>CD4<jats:sup>+</jats:sup> and CD3<jats:sup>+</jats:sup>CD8<jats:sup>+</jats:sup> effector memory cells were higher, while CD25<jats:sup>+</jats:sup>Foxp3<jats:sup>+</jats:sup> T regulatory cells were lower. In addition, both transitional B cell and plasmablast levels were significantly elevated in COVID‐19‐infected patients. Fever (duration, level) correlated with numbers of central memory CD4<jats:sup>+</jats:sup> T cells and anti‐S and anti‐RBD, but not anti‐NC antibody levels. Moreover, a “young immunological age” as determined by numbers of CD3<jats:sup>+</jats:sup>CD45RA<jats:sup>+</jats:sup>CD62L<jats:sup>+</jats:sup>CD31<jats:sup>+</jats:sup> recent thymic emigrants was associated with a loss of sense of taste and/or smell.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Acute SARS‐CoV‐2 infection leaves protracted beneficial (ie, activation of T cells) and potentially harmful (ie, reduction of neutrophils) imprints in the cellular immune system in addition to induction of specific antibody responses.</jats:p></jats:sec>

収録刊行物

  • Allergy

    Allergy 76 (3), 751-765, 2020-11-22

    Wiley

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ